The rapid progression and poor prognosis of pancreatic cancer: a therapeutic lead.
Pancreatic cancer is a disease with a poor prognosis that progresses very rapidly after detection to metastatic spread. At detection, the primary tumour may be associated with a so-called micro-metastatic disease which, because it is microscopic, goes unnoticed with our current imaging techniques. Our CRCT team, in collaboration with a CRCT team and several international teams, has been able to demonstrate that the activation of a signalling pathway is necessary for the transition from the micro-metastatic state to their development into macro-metastases, which are visible metastases. This is the PI3K pathway, which is altered in more than half of all solid cancers. Our results also demonstrate the efficacy of PI3K inhibitors on this progression.
Discover the published article
EMBO Mol Med. 2021 Jul 7;13(7):e13502.doi: 10.15252/emmm.202013502. Epub 2021 May 25.
Pancreatic Cancer Intrinsic PI3K Activity accelerates Metastasis and rewires Macrophage Component
Thibault B, Ramos Delgado F, Pons-Tostivint E, Therville N, Cintas C, Arcucci S, Cassant-Sourdy S, Reyes-Castellanos G, Tosolini M, Villard A.V, Cayron C, Baer R, Bertrand-Michel J, Pagan D, Ferreira Da Mota D, Yan H, Falcomatà C, Muscari F, Bournet B, Delord JP, Aksoy E, Carrier A, Cordelier P, Saur D. 6, Basset C, Guillermet-Guibert J
Toulouse Cancer Research Center (Oncopole)
Toulouse – FR
+33 5 82 74 15 75
Want to join
the CRCT team ?